{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T13:04:49Z","timestamp":1793883889084,"version":"4.7.0"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004564","name":"Ministarstvo Prosvete, Nauke i Tehnolo\u0161kog Razvoja","doi-asserted-by":"publisher","award":["173023"],"award-info":[{"award-number":["173023"]}],"id":[{"id":"10.13039\/501100004564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004564","name":"Ministarstvo Prosvete, Nauke i Tehnolo\u0161kog Razvoja","doi-asserted-by":"publisher","award":["175045"],"award-info":[{"award-number":["175045"]}],"id":[{"id":"10.13039\/501100004564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.pnpbp.2020.109975","type":"journal-article","created":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T20:41:33Z","timestamp":1590439293000},"page":"109975","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Vortioxetine reduces pain hypersensitivity and associated depression-like behavior in mice with oxaliplatin-induced neuropathy"],"prefix":"10.1016","volume":"103","author":[{"given":"Ana M.","family":"Micov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja A.","family":"Tomi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marija B.","family":"Todorovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milja J.","family":"Vukovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uro\u0161 B.","family":"Pecikoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nebojsa I.","family":"Jasnic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena D.","family":"Djordjevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radica M.","family":"Stepanovi\u0107-Petrovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2020.109975_bb0005","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/pm\/pnz120","article-title":"Vortioxetine in the treatment of mood disorders associated with burning mouth syndrome: results of an open-label, flexible-dose pilot study","volume":"21","author":"Adamo","year":"2020","journal-title":"Pain Med."},{"key":"10.1016\/j.pnpbp.2020.109975_bb0010","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.neuroscience.2010.04.032","article-title":"Subtype-specific changes in 5-HT receptor-mediated modulation of C fibre-evoked spinal field potentials are triggered by peripheral nerve injury","volume":"168","author":"Aira","year":"2010","journal-title":"Neuroscience."},{"key":"10.1016\/j.pnpbp.2020.109975_bb0015","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.nurt.2009.07.003","article-title":"Animal models of chemotherapy-evoked painful peripheral neuropathies","volume":"6","author":"Authier","year":"2009","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.pnpbp.2020.109975_bb0020","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.brainres.2015.06.043","article-title":"Role of spinal 5-HT5A, and 5-HT1A\/1B\/1D, receptors in neuropathic pain induced by spinal nerve ligation in rats","volume":"1622","author":"Avila-Rojas","year":"2015","journal-title":"Brain Res."},{"key":"10.1016\/j.pnpbp.2020.109975_bb0025","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ejphar.2014.04.028","article-title":"Serotonergic modulation in neuropathy induced by oxaliplatin: effect on the 5HT2C receptor","volume":"735","author":"Baptista-de-Souza","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pnpbp.2020.109975_bb0030","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/FBP.0b013e328349aae4","article-title":"The complex role of serotonin and 5-HT receptors in chronic pain","volume":"22","author":"Bardin","year":"2011","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.pnpbp.2020.109975_bb0035","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1097\/j.pain.0000000000000372","article-title":"Role of brainstem serotonin in analgesia produced by low-intensity exercise on neuropathic pain after sciatic nerve injury in mice","volume":"156","author":"Bobinski","year":"2015","journal-title":"Pain"},{"key":"10.1016\/j.pnpbp.2020.109975_bb0040","article-title":"The mouse forced swim test","volume":"59","author":"Can","year":"2012","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.pnpbp.2020.109975_bb0045","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.neulet.2014.10.014","article-title":"Chemotherapy-induced peripheral neuropathy: what do we know about mechanisms?","volume":"596","author":"Carozzi","year":"2015","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.pnpbp.2020.109975_bb0050","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/j.1532-2149.2012.00221.x","article-title":"Spinal 5-HT3 receptors facilitate behavioural hypersensitivity induced by elevated calcium channel alpha-2-delta-1 protein","volume":"17","author":"Chang","year":"2013","journal-title":"Eur. J. Pain"},{"key":"10.1016\/j.pnpbp.2020.109975_bb0055","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/0304-3959(94)90023-X","article-title":"Behavioral signs of ongoing pain and cold allodynia in a rat model of neuropathic pain","volume":"59","author":"Choi","year":"1994","journal-title":"Pain"},{"key":"10.1016\/j.pnpbp.2020.109975_bb0060","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.jad.2017.11.081","article-title":"Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: a novel dual outcome measure in depressive disorders","volume":"227","author":"Christensen","year":"2018","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.pnpbp.2020.109975_bb0065","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/S0140-6736(09)60046-5","article-title":"Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis","volume":"373","author":"Cipriani","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.pnpbp.2020.109975_bb0070","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jad.2016.02.042","article-title":"Vortioxetine for major depressive disorder: an indirect comparison with duloxetine, escitalopram, levomilnacipran, sertraline, venlafaxine, and vilazodone, using number needed to treat, number needed to harm, and likelihood to be helped or harmed","volume":"196","author":"Citrome","year":"2016","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.pnpbp.2020.109975_bb0075","doi-asserted-by":"crossref","first-page":"504691","DOI":"10.1155\/2015\/504691","article-title":"Neuroplasticity underlying the comorbidity of pain and depression","volume":"2015","author":"Doan","year":"2015","journal-title":"Neural Plast."},{"key":"10.1016\/j.pnpbp.2020.109975_bb0080","series-title":"Wall and Melzack\u2019s Textbook of Pain","first-page":"273","article-title":"Psychiatric pain-associated co-morbidities","author":"Fishbain","year":"2013"},{"key":"10.1016\/j.pnpbp.2020.109975_bb0085","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.neulet.2009.04.029","article-title":"Involvement of increased expression of transient receptor potential melastatin 8 in oxaliplatin-induced cold allodynia in mice","volume":"458","author":"Gauchan","year":"2009","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.pnpbp.2020.109975_bb0090","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1152\/jn.2001.85.5.2293","article-title":"A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels","volume":"85","author":"Grolleau","year":"2001","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.pnpbp.2020.109975_bb0095","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/ejp.550","article-title":"Antinociceptive activity of the new triple reuptake inhibitor NS18283 in a mouse model of chemotherapy-induced neuropathic pain","volume":"19","author":"Hache","year":"2015","journal-title":"Eur. J. Pain"},{"key":"10.1016\/j.pnpbp.2020.109975_bb0100","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.pnpbp.2013.04.009","article-title":"Monoamine neurocircuitry in depression and strategies for new treatments","volume":"45","author":"Hamon","year":"2013","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2020.109975_bb0105","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1200\/JCO.2013.54.0914","article-title":"Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline","volume":"32","author":"Hershman","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.pnpbp.2020.109975_bb0110","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/SPC.0000000000000204","article-title":"Chemotherapy-induced painful neuropathy: pain-like behaviours in rodent models and their response to commonly used analgesics","volume":"10","author":"Hopkins","year":"2016","journal-title":"Curr. Opin. Support. Palliat. Care"},{"key":"10.1016\/j.pnpbp.2020.109975_bb0115","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.neulet.2016.03.019","article-title":"Duloxetine and 8-OH-DPAT, but not fluoxetine, reduce depression-like behaviour in an animal model of chronic neuropathic pain","volume":"619","author":"Hu","year":"2016","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.pnpbp.2020.109975_bb0120","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.bbi.2017.03.005","article-title":"The novel and potent anti-depressive action of triptolide and its influences on hippocampal neuroinflammation in a rat model of depression comorbidity of chronic pain","volume":"64","author":"Hu","year":"2017","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.pnpbp.2020.109975_bb0125","doi-asserted-by":"crossref","first-page":"184","DOI":"10.2174\/1570159X15666170915143217","article-title":"Prevention and treatment for chemotherapy-induced peripheral neuropathy: therapies based on CIPN mechanisms","volume":"17","author":"Hu","year":"2019","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.pnpbp.2020.109975_bb0130","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s00280-009-1085-7","article-title":"Extracellular fluid concentrations of cisplatin, carboplatin, and oxaliplatin in brain, muscle, and blood measured using microdialysis in nonhuman primates","volume":"65","author":"Jacobs","year":"2010","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.pnpbp.2020.109975_bb0135","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00213-010-1977-6","article-title":"Depression-like behavior and mechanical allodynia are reduced by bis selenide treatment in mice with chronic constriction injury: a comparison with fluoxetine, amitriptyline, and bupropion","volume":"212","author":"Jesse","year":"2010","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2020.109975_bb0140","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/YIC.0b013e3283542457","article-title":"A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder","volume":"27","author":"Katona","year":"2012","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2020.109975_bb0145","series-title":"Pharmacology of Pain","first-page":"185","article-title":"Toward deciphering the respective roles of multiple 5-HT receptors in the complex serotonin-mediated control of pain","author":"Kayser","year":"2010"},{"key":"10.1016\/j.pnpbp.2020.109975_bb0150","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3389\/fphar.2017.00086","article-title":"Long-term effects, pathophysiological mechanisms, and risk factors of chemotherapy-induced peripheral neuropathies: a comprehensive literature review","volume":"8","author":"Kerckhove","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.pnpbp.2020.109975_bb0155","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/ACO.0000000000000500","article-title":"Chemotherapy-induced peripheral neuropathy: a review of recent findings","volume":"30","author":"Kim","year":"2017","journal-title":"Curr. Opin. Anaesthesiol."},{"issue":"12","key":"10.1016\/j.pnpbp.2020.109975_bb0160","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.3390\/ijms18122626","article-title":"Duloxetine protects against oxaliplatin-induced neuropathic pain and spinal neuron hyperexcitability in rodents","volume":"18","author":"Kim","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.pnpbp.2020.109975_bb0165","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.1111\/bph.12782","article-title":"Multimodal antidepressant vortioxetine increases frontal cortical oscillations unlike escitalopram and duloxetine \u2013 a quantitative EEG study in rats","volume":"171","author":"Leiser","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pnpbp.2020.109975_bb0170","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1007\/s11064-013-1103-3","article-title":"Repeated administration of mirtazapine attenuates oxaliplatin-induced mechanical allodynia and spinal NR2B up-regulation in rats","volume":"38","author":"Liu","year":"2013","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.pnpbp.2020.109975_bb0175","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.expneurol.2017.10.007","article-title":"Monoaminergic descending pathways contribute to modulation of neuropathic pain by increasing-intensity treadmill exercise after peripheral nerve injury","volume":"299","author":"Lopez-Alvarez","year":"2018","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.pnpbp.2020.109975_bb0180","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1038\/npp.2015.52","article-title":"A randomized, placebo-controlled, active-reference, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder","volume":"40","author":"Mahableshwarkar","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2020.109975_bb0185","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.lfs.2013.12.229","article-title":"Neurotropin\u00ae relieves oxaliplatin-induced neuropathy via Gi protein-coupled receptors in the monoaminergic descending pain inhibitory system","volume":"98","author":"Masuguchi","year":"2014","journal-title":"Life Sci."},{"key":"10.1016\/j.pnpbp.2020.109975_bb0190","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/S0022-3565(25)24527-X","article-title":"Modulation of norepinephrine release by serotonergic receptors in the rat hippocampus as measured by in vivo microdialysis","volume":"272","author":"Matsumoto","year":"1995","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pnpbp.2020.109975_bb0195","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.phrs.2015.04.014","article-title":"Levetiracetam synergises with common analgesics in producing antinociception in a mouse model of painful diabetic neuropathy","volume":"97","author":"Micov","year":"2015","journal-title":"Pharmacol. Res."},{"issue":"11","key":"10.1016\/j.pnpbp.2020.109975_bb0200","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18112483","article-title":"Analgesic mechanisms of antidepressants for neuropathic pain","volume":"18","author":"Obata","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.pnpbp.2020.109975_bb0205","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.clinph.2017.12.028","article-title":"Oxaliplatin and neuropathy: a role for sodium channels","volume":"129","author":"Park","year":"2018","journal-title":"Clin. Neurophysiol."},{"key":"10.1016\/j.pnpbp.2020.109975_bb0210","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.euroneuro.2012.04.006","article-title":"Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters \u2013 a rat microdialysis and electrophysiology study","volume":"23","author":"Pehrson","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2020.109975_bb0215","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.pneurobio.2006.08.001","article-title":"Noradrenergic pain modulation","volume":"80","author":"Pertovaara","year":"2006","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.pnpbp.2020.109975_bb0220","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.neuropharm.2018.07.026","article-title":"Targeting the TREK-1 potassium channel via riluzole to eliminate the neuropathic and depressive-like effects of oxaliplatin","volume":"140","author":"Poupon","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pnpbp.2020.109975_bb0225","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","article-title":"Dose translation from animal to human studies revisited","volume":"22","author":"Reagan-Shaw","year":"2008","journal-title":"FASEB J."},{"key":"10.1016\/j.pnpbp.2020.109975_bb0230","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.bbr.2014.12.052","article-title":"Bidirectional amygdaloid control of neuropathic hypersensitivity mediated by descending serotonergic pathways acting on spinal 5-HT3 and 5-HT1A receptors","volume":"282","author":"Sagalajev","year":"2015","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.pnpbp.2020.109975_bb0235","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1111\/cbdd.13507","article-title":"Searching for analgesic drug candidates alleviating oxaliplatin- induced cold hypersensitivity in mice","volume":"93","author":"Sa\u0142at","year":"2019","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.pnpbp.2020.109975_bb0240","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.pharmthera.2014.07.001","article-title":"Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data","volume":"145","author":"Sanchez","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.pnpbp.2020.109975_bb0245","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1007\/s00213-019-05274-4","article-title":"Vortioxetine reverses medial prefrontal cortex-mediated cognitive deficits in male rats induced by castration as a model of androgen deprivation therapy for prostate cancer","volume":"236","author":"Sharp","year":"2019","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2020.109975_bb0250","doi-asserted-by":"crossref","first-page":"9724371","DOI":"10.1155\/2017\/9724371","article-title":"The link between depression and chronic pain: neural mechanisms in the brain","volume":"2017","author":"Sheng","year":"2017","journal-title":"Neural Plast."},{"key":"10.1016\/j.pnpbp.2020.109975_bb0255","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jama.2013.2813","article-title":"Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial","volume":"309","author":"Smith","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.pnpbp.2020.109975_bb0260","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.pharep.2017.01.030","article-title":"Vortioxetine: a review of the pharmacology and clinical profile of the novel antidepressant","volume":"69","author":"Sowa-Ku\u0107ma","year":"2017","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.pnpbp.2020.109975_bb0265","series-title":"Neuroproteomics, Neuromethods","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/978-1-61779-111-6_2","article-title":"Dissection of rodent brain regions","volume":"Vol. 57","author":"Spijker","year":"2011"},{"key":"10.1016\/j.pnpbp.2020.109975_bb0270","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/ana.24951","article-title":"Chemotherapy-induced peripheral neuropathy: a current review","volume":"81","author":"Staff","year":"2017","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.pnpbp.2020.109975_bb0275","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/j.euroneuro.2016.07.005","article-title":"Melatonin mediated antidepressant-like effect in the hippocampus of chronic stress-induced depression rats: regulating vesicular monoamine transporter 2 and monoamine oxidase A levels","volume":"26","author":"Stefanovic","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2020.109975_bb0280","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0006-8993(00)01941-7","article-title":"Effect of a 5-HT(1A) receptor agonist, flesinoxan, on the extracellular noradrenaline level in the hippocampus and on the locomotor activity of rats","volume":"858","author":"Suwabe","year":"2000","journal-title":"Brain Res."},{"key":"10.1016\/j.pnpbp.2020.109975_bb0285","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1476-5381.1995.tb14990.x","article-title":"Increase of noradrenaline release in the hypothalamus of freely moving rat by postsynaptic 5-hydroxytryptamine1A receptor activation","volume":"115","author":"Suzuki","year":"1995","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pnpbp.2020.109975_bb0290","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0304-3959(99)00018-4","article-title":"Hyperalgesia due to nerve damage: role of nerve growth factor","volume":"81","author":"Theodosiou","year":"1999","journal-title":"Pain"},{"key":"10.1016\/j.pnpbp.2020.109975_bb0295","first-page":"3307","article-title":"Oxaliplatin-induced peripheral neuropathy\u2019s effects on health-related quality of life of colorectal cancer survivors","volume":"21","author":"Tofthagen","year":"2013","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.pnpbp.2020.109975_bb0300","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.neuropharm.2017.02.020","article-title":"Effects of paclitaxel on the development of neuropathy and affective behaviors in the mouse","volume":"117","author":"Toma","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pnpbp.2020.109975_bb0305","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1517\/17460441.2012.693912","article-title":"Preclinical discovery of duloxetine for the treatment of depression","volume":"7","author":"Torres-Sanchez","year":"2012","journal-title":"Expert Opin. Drug Discovery"},{"key":"10.1016\/j.pnpbp.2020.109975_bb0310","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1097\/j.pain.0000000000000404","article-title":"Chemotherapy-induced pain and neuropathy: a prospective study in patients treated with adjuvant oxaliplatin or docetaxel","volume":"157","author":"Ventzel","year":"2016","journal-title":"Pain"},{"key":"10.1016\/j.pnpbp.2020.109975_bb0315","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejphar.2013.01.074","article-title":"Multiple roles of serotonin in pain control mechanisms--implications of 5-HT\u2087 and other 5-HT receptor types","volume":"716","author":"Viguier","year":"2013","journal-title":"Eur. J. Pharmacol."},{"issue":"3 Suppl","key":"10.1016\/j.pnpbp.2020.109975_bb0320","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.pain.2010.09.030","article-title":"Central sensitization: implications for the diagnosis and treatment of pain","volume":"152","author":"Woolf","year":"2011","journal-title":"Pain"},{"key":"10.1016\/j.pnpbp.2020.109975_bb0325","doi-asserted-by":"crossref","DOI":"10.1177\/1744806918808987","article-title":"The multimodal antidepressant vortioxetine causes analgesia in a mouse model of chronic neuropathic pain","volume":"14","author":"Zuena","year":"2018","journal-title":"Mol. Pain"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584620302918?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584620302918?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T19:52:09Z","timestamp":1759521129000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584620302918"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":65,"alternative-id":["S0278584620302918"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2020.109975","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vortioxetine reduces pain hypersensitivity and associated depression-like behavior in mice with oxaliplatin-induced neuropathy","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2020.109975","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109975"}}